Fastest Growing Stocks
PHARM.AS is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
PHARMING GROUP NV (PHARM.AS) Stock Price & Overview
AMS:PHARM • NL0010391025
Current stock price
1.516 EUR
-0.01 (-0.72%)
Last:
The current stock price of PHARM.AS is 1.516 EUR. Today PHARM.AS is down by -0.72%. In the past month the price increased by 12.86%. In the past year, price increased by 117.83%.
PHARM.AS Key Statistics
52-Week Range0.686 - 1.818
Current PHARM.AS stock price positioned within its 52-week range.
1-Month Range1.301 - 1.5895
Current PHARM.AS stock price positioned within its 1-month range.
- Market Cap
- 1.063B
- P/E
- N/A
- Fwd P/E
- 50.40
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
PHARM.AS Stock Performance
Today
-0.72%
1 Week
+3.88%
1 Month
+12.86%
3 Months
-4.44%
Longer-term
6 Months +27.14%
1 Year +117.83%
2 Years +74.22%
3 Years +49.41%
5 Years +43.85%
10 Years +610.23%
PHARM.AS Stock Chart
PHARM.AS Stock Screens
PHARM.AS currently appears in the following ChartMill screener lists.
Strong Buy Rated Stocks
PHARM.AS is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
Minervini Stocks
PHARM.AS is part of our Minervini Stocks list, indicating it shows strong fundamental growth characteristics and technical strength.
PHARM.AS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PHARM.AS. When comparing the yearly performance of all stocks, PHARM.AS is one of the better performing stocks in the market, outperforming 95.21% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PHARM.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS. While PHARM.AS has a great health rating, its profitability is only average at the moment.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PHARM.AS Earnings
On March 12, 2026 PHARM.AS reported an EPS of 0.01 and a revenue of 106.53M. The company missed EPS expectations (-6.76% surprise) and missed revenue expectations (-1.68% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported$0.01
Revenue Reported106.533M
EPS Surprise -6.76%
Revenue Surprise -1.68%
PHARM.AS Forecast & Estimates
14 analysts have analysed PHARM.AS and the average price target is 2.26 EUR. This implies a price increase of 48.86% is expected in the next year compared to the current price of 1.516.
For the next year, analysts expect an EPS growth of 1671.6% and a revenue growth 8.86% for PHARM.AS
Analysts
Analysts88.57
Price Target2.26 (49.08%)
EPS Next Y1671.6%
Revenue Next Year8.86%
PHARM.AS Groups
Sector & Classification
PHARM.AS Financial Highlights
Income Statements
Revenue(TTM)376.13M
Net Income(TTM)2.85M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.76% | ||
| ROA | 0.57% | ||
| ROE | 1.03% | ||
| Debt/Equity | 0.39 |
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%14.96%
EPS 1Y (TTM)111.11%
Revenue 1Y (TTM)26.56%
PHARM.AS Ownership
Ownership
Inst Owners21.67%
Shares701.40M
Float688.06M
Ins Owners0.13%
Short Float %N/A
Short RatioN/A
PHARM.AS Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 30.83 | 43.947B | ||
| ARGX | ARGENX SE | 30.77 | 43.935B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.305B | ||
| ABVX | ABIVAX SA | N/A | 8.214B | ||
| 2X1 | ABIVAX SA | N/A | 8.191B | ||
| GLPG | GALAPAGOS NV | N/A | 1.621B | ||
| GXE | GALAPAGOS NV | N/A | 1.619B | ||
| NANO | NANOBIOTIX | N/A | 1.361B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.068B | ||
| PHGN | PHARMING GROUP NV | 49.87 | 1.052B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.013B | ||
| IVA | INVENTIVA SA | N/A | 960.659M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Amsterdam Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About PHARM.AS
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
IPO: 1998-07-02
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 407
Phone: 31715247400
PHARMING GROUP NV / PHARM.AS FAQ
What does PHARMING GROUP NV do?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
What is the current price of PHARM stock?
The current stock price of PHARM.AS is 1.516 EUR. The price decreased by -0.72% in the last trading session.
Does PHARM stock pay dividends?
PHARM.AS does not pay a dividend.
How is the ChartMill rating for PHARMING GROUP NV?
PHARM.AS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the sector and industry classification for PHARMING GROUP NV?
PHARMING GROUP NV (PHARM.AS) operates in the Health Care sector and the Biotechnology industry.
Who owns PHARMING GROUP NV?
You can find the ownership structure of PHARMING GROUP NV (PHARM.AS) on the Ownership tab.